Nectar Lifesciences Extends Deadline for Empty Hard Gelatin Capsule Business Slump Sale
Nectar Lifesciences Limited has announced an extension to the completion date of the slump sale involving its Empty Hard Gelatin Capsule business. The transaction, which is being executed on a lump sum basis, involves Capnest Health Care Private Limited as the purchaser.The Company and Capnest Health Care Private Limited have mutually agreed to extend the expected completion date for the transfer of the Empty Hard Gelatin Capsule business. The new deadline set for the slump sale is on or before December 31, 2026.
The extension relates to the ongoing process of transferring the business previously disclosed by Nectar Lifesciences Limited. All other relevant details pertaining to the lump sum sale remain consistent with earlier disclosures made regarding the transaction.
NECLIFE Stock Price Movement
Today, Nectar Lifesciences Limited shares shed value, slipping 1.42% to settle at ₹10.36 in post-market trading. The stock traded a volume of 76,356 shares after hitting an intraday low of ₹10.30.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.